SARS-CoV-2 Spike glycoprotein receptor-binding domain (Omicron variant) (RBD)

The SARS-CoV-2 Omicron receptor-binding domain (RBD) is a critical segment of the S1 subunit of the spike protein, specifically within the B.1.1.529 lineage and its subsequent sub-lineages [PubMed: 35016194]. It serves as the primary attachment point where the virus docks onto the human Angiotensin-Converting Enzyme 2 (ACE2) receptor to initiate the infection process [UniProt: P0DTC2]. Compared to the ancestral strain, the Omicron RBD contains a high density of mutations—often exceeding 15 amino acid substitutions—that increase its binding affinity for ACE2 while significantly reducing the effectiveness of many therapeutic monoclonal antibodies [PubMed: 35381044]. As a therapeutic target, the RBD is the focus of vaccine-induced neutralizing antibodies and engineered biologics designed to prevent viral entry [NIH: COVID-19 Treatment Guidelines]. The rapid emergence of subvariants like BA.2, BA.5, and XBB has led to a continuous challenge in drug development, as these mutations often reside in key antigenic sites, rendering many first-generation treatments obsolete [PubMed: 36544040]. Consequently, the RBD is a primary target for monitoring viral fitness and developing next-generation pan-sarbecovirus therapeutics.

Other names

SARS-CoV-2 Omicron RBDOmicron variant Spike RBDS1-RBD (Omicron)B.1.1.529 Spike RBDSARS-CoV-2 Receptor-Binding Domain

Neutralizing antibodies and vaccines target the RBD to sterically hinder its interaction with the human Angiotensin-Converting Enzyme 2 (ACE2) receptor, thereby preventing viral attachment and subsequent entry into host cells.